title: Efficacy of aflibercept (EYLEA®) on inhibition of human VEGF in vitro.
abstract: BACKGROUND
  Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several serious ophthalmological diseases such as wet age-related macular degeneration (AMD) or diabetic retinopathy. In AMD treatment, aflibercept (tradename EYLEA®) is used to deactivate the underlying pathological neovascularisation. Aflibercept is a recombinant fusion protein which binds to vascular endothelial growth factor (VEGF) receptors, thereby inhibiting VEGF pathway activation. VEGF is one of the most important angiogenesis factors.
  
  
  OBJECTIVE
  This analysis investigates lasting efficacy of aflibercept in vitro for later application as therapeutic agent against macular degeneration (AMD).
  
  
  METHODS
  VEGF-ELISA assays were performed to investigate binding affinities at different aflibercept concentrations. The impact of VEGF on the proliferation of human umbilical vein endothelial cells (HUVEC) was investigated using proliferation assays. Moreover, time-dependent kinetic studies were performed to analyze different aflibercept storage durations with regard to its inhibitory capabilities on human VEGF.
  
  
  CONCLUSIONS
  Our results reveal that aflibercept significantly lowers the amount of unbound VEGF as well as the proliferation rate of HUVEC. Moreover, in contrast to specifications given by the manufacturer, aflibercept retains its full inhibitory effect up to at least 120h after transference from the original vial into the injection syringe.
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany. Electronic address: martin.schicht@fau.de.
authors.forename: M
authors.initials: M
authors.lastname: Schicht
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Hesse
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schröder
authors.affiliation: Department of Surgery, Division of Molecular and Experimental Surgery, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: E
authors.initials: E
authors.lastname: Naschberger
authors.affiliation: Pharmacy at the Bohlenplatz, Erlangen, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Lamprecht
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: F
authors.initials: F
authors.lastname: Garreis
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: F P
authors.initials: FP
authors.lastname: Paulsen
authors.affiliation: Institute of Anatomy, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Bräuer
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004355:Drug Stability; D004356:Drug Storage; D042783:Endothelial Cells / Q000187:drug effects* / Q000502:physiology*; D006801:Humans; D040262:Receptors, Vascular Endothelial Growth Factor / Q000008:administration & dosage*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D020533:Angiogenesis Inhibitors; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; D040262:Receptors, Vascular Endothelial Growth Factor
keywords: Aflibercept; EYLEA(®); HUVEC; VEGF; VEGF-trap